CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic ...

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated ...

CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock ...

Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the ...

CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (XCUR) (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU ...

Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and ...

We recently compiled a list of the 10 Micro-, Small-Cap Companies Lead Monday’s Charge. In this article, we are going to take a look at where Exicure Inc. (NASDAQ:XCUR) stands against the other stocks ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Exicure, Inc. (NASDAQ: XCUR) between March 11, 2021 and November 15, 2021, inclusive (the "Class Period" ...

CHICAGO--(BUSINESS WIRE)-- Please replace the release dated December 20, 2024 with the following corrected version due to multiple revisions. The updated release ...

REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025. Third ...